A Phase I Study of SOR-C13 in Patients With Advanced Solid Tumors
Public ClinicalTrials.gov record NCT03784677. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This phase I trial studies the side effects and best dose of SOR-C13 in treating patients with solid tumors that have spread to other places in the body (advanced) and does not respond to treatment. Drugs used in chemotherapy, such as SOR-C13, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Study identification
- NCT ID
- NCT03784677
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 11 participants
Conditions and interventions
Conditions
- Advanced Malignant Solid Neoplasm
- Refractory Malignant Solid Neoplasm
- Refractory Ovarian Carcinoma
- Refractory Pancreatic Carcinoma
- Stage II Pancreatic Cancer AJCC v8
- Stage IIA Pancreatic Cancer AJCC v8
- Stage IIB Pancreatic Cancer AJCC v8
- Stage III Ovarian Cancer AJCC v8
- Stage III Pancreatic Cancer AJCC v8
- Stage III Prostate Cancer AJCC v8
- Stage IIIA Ovarian Cancer AJCC v8
- Stage IIIA Prostate Cancer AJCC v8
- Stage IIIB Ovarian Cancer AJCC v8
- Stage IIIB Prostate Cancer AJCC v8
- Stage IIIC Ovarian Cancer AJCC v8
- Stage IIIC Prostate Cancer AJCC v8
- Stage IV Ovarian Cancer AJCC v8
- Stage IV Pancreatic Cancer AJCC v8
- Stage IV Prostate Cancer AJCC v8
- Stage IVA Ovarian Cancer AJCC v8
- Stage IVA Prostate Cancer AJCC v8
- Stage IVB Ovarian Cancer AJCC v8
- Stage IVB Prostate Cancer AJCC v8
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 29, 2019 (Actual)
- Primary completion
- Jun 20, 2023 (Actual)
- Completion
- Jun 20, 2023 (Actual)
- Last update posted
- Nov 18, 2023
2019 – 2023
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| M D Anderson Cancer Center | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03784677, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 18, 2023 · Synced Oct 28, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03784677 live on ClinicalTrials.gov.